News stories about PAVmed (NASDAQ:PAVM) have been trending somewhat negative this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. PAVmed earned a media sentiment score of -0.16 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.8511527400248 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- PAVmed Closes Oversubscribed Rights Offering for Gross Proceeds of $10,350,000 (finance.yahoo.com)
- PAVmed Inc (PAVM) Major Shareholder Ira Scott Greenspan Sells 18,300 Shares (americanbankingnews.com)
- Rights offering expected to pull in about $10.4M for PAVmed (smartbrief.com)
- Pavmed lands $10m from oversubscribed rights offering (massdevice.com)
- PAVmed to receive $10.4M from rights offering; shares ahead 14% premarket (seekingalpha.com)
Separately, ValuEngine raised shares of PAVmed from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
PAVmed (NASDAQ:PAVM) last released its quarterly earnings data on Monday, May 21st. The company reported ($0.21) earnings per share (EPS) for the quarter. research analysts expect that PAVmed will post -0.4 earnings per share for the current year.
In other news, major shareholder Ira Scott Greenspan sold 532,255 shares of the company’s stock in a transaction that occurred on Friday, June 1st. The shares were sold at an average price of $0.97, for a total value of $516,287.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 79.30% of the stock is owned by insiders.
PAVmed Company Profile
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.